EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Chronic hepatitis D in Austria: high burden of cirrhosis and portal hypertension, IL28B C/C as unfavorable factor, increased systemic inflammation in decompensation

Michael Schwarz, Caroline Schwarz, David J M Bauer, Marlene Panzer, Marlene Hintersteininger, Michael Strasser, Silvia Reiter, Livia Dorn, Michael Trauner, Albert Friedrich Stättermayer, Mattias Mandorfer, Andreas Maieron und 6 weitere

Wiener klinische Wochenschrift · 2026-08 · 138 (15-16) · 483-494

DOI: 10.1007/s00508-026-02700-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Wiener klinische Wochenschrift, online erschienen am 05.02.2026. Verfasst von Michael Schwarz und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austri…. Hauptthemen laut MEDLINE: Hypertension, Portal, Interleukins, Liver Cirrhosis, Hepatitis D, Chronic. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic hepatitis D (CHD) is a severe viral hepatitis characterized by a rapid progression towards advanced chronic liver disease (ACLD). This study aimed to characterize the Austrian CHD epidemiology with respect to disease severity, systemic inflammation and genetic markers.

Methods

Patients attending one of six participating hospitals from 2020 onwards were included and assessed regarding laboratory data, liver stiffness measurement (LSM) and biopsy, hepatic venous pressure gradient (HVPG) measurement, endoscopy and imaging. In a subset, single nucleotide polymorphisms (SNPs) in genes of interest (IL28B, PNPLA3, SERPINA1, NTCP) were assessed. Biomarkers of liver disease severity were compared to an age-matched cohort of treatment-eligible and treatment-naïve chronic hepatitis B (CHB) patients.

Results

A total of 59 CHD patients (median age: 44.0 years, 59.3% male) were included and ACLD was found in 62.7%. Decompensated patients exhibited higher levels of biomarkers of systemic inflammation, such as C‑reactive protein ( p = 0.061) and interleukin 6 ( p = 0.008). The SNP IL28B C/C genotype had an unfavorable effect on disease severity (higher Model for End-Stage Liver Disease [MELD] score, HVPG and ammonia levels, lower platelet counts and albumin levels, all p < 0.05). The CHD patients showed a more severe liver disease compared to CHB mono-infected patients with respect to LSM, platelets, MELD and portal hypertension (all p < 0.01).

Conclusion

This analysis of the Austrian CHD cohort before initiation of antiviral treatment showed a high burden of ACLD and portal hypertension, especially when compared to CHB patients. The IL28B C/C SNP was associated with a more severe liver disease in CHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PortalInterleukinsLiver CirrhosisHepatitis D, ChronicHumansMaleFemaleAustriaAdultMiddle AgedInterferon LambdaInterferonsPolymorphism, Single NucleotideGenetic MarkersDisease Progression

Stichwörter der Autor:innen

ACLDGenetic markersLiver diseaseViral hepatitis

Substanzen

InterleukinsInterferon Lambdainterferon-lambda, humanInterferonsGenetic Markers

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
  • Department of Internal Medicine 2, University Hospital of St. Pölten, St. Pölten, Austria.
  • Rare Liver Disease (RALID) Center of the European Reference Network for Rare Hepatological Diseases (ERN RARE-LIVER), Medical University Vienna, Vienna, Austria.
  • Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.
  • Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.
  • First Department of Medicine, Paracelsus Medical University, Salzburg, Austria.

Förderung

  • Gilead Sciences
  • Medical University of Vienna

Zitieren

APA

Schwarz, M., Schwarz, C., Bauer, D. J. M., Panzer, M., Hintersteininger, M., Strasser, M., Reiter, S., Dorn, L., Trauner, M., Stättermayer, A. F., Mandorfer, M., Maieron, A., Moschen, A., Aigner, E., Zoller, H., Gschwantler, M., Reiberger, T., & Jachs, M. (2026). Chronic hepatitis D in Austria: high burden of cirrhosis and portal hypertension, IL28B C/C as unfavorable factor, increased systemic inflammation in decompensation. Wiener klinische Wochenschrift, 138(15-16), 483-494. https://doi.org/10.1007/s00508-026-02700-4

Vancouver

Schwarz M, Schwarz C, Bauer DJM, Panzer M, Hintersteininger M, Strasser M, et al. Chronic hepatitis D in Austria: high burden of cirrhosis and portal hypertension, IL28B C/C as unfavorable factor, increased systemic inflammation in decompensation. Wiener klinische Wochenschrift. 2026;138(15-16):483-494. doi:10.1007/s00508-026-02700-4

BibTeX
@article{Schwarz2026,
  author = {Schwarz, Michael and Schwarz, Caroline and Bauer, David J M and Panzer, Marlene and Hintersteininger, Marlene and Strasser, Michael and Reiter, Silvia and Dorn, Livia and Trauner, Michael and Stättermayer, Albert Friedrich and Mandorfer, Mattias and Maieron, Andreas and Moschen, Alexander and Aigner, Elmar and Zoller, Heinz and Gschwantler, Michael and Reiberger, Thomas and Jachs, Mathias},
  title = {Chronic hepatitis D in Austria: high burden of cirrhosis and portal hypertension, IL28B C/C as unfavorable factor, increased systemic inflammation in decompensation},
  journal = {Wiener klinische Wochenschrift},
  year = {2026},
  volume = {138},
  number = {15-16},
  pages = {483--494},
  doi = {10.1007/s00508-026-02700-4}
}
Kostenlos starten →